Chih-Hsin Yang - JoVE Visualize

Showing results (271-280 of 324) with videos related to

Pageof 33

Sort By:

Clinical Lung Cancer|April 15, 2018

Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 TrialsYi-Long Wu, Lecia V Sequist, Eng-Huat Tan, et al.

Proceedings of the National Academy of Sciences of the United States of America|December 21, 2007

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibJames Bean, Cameron Brennan, Jin-Yuan Shih, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2017

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension ComponentJames Chih-Hsin Yang, Myung-Ju Ahn, Dong-Wan Kim, et al.

Cancer Discovery|September 22, 2021

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung CancerPasi A Jänne, Christina Baik, Wu-Chou Su, et al.

Future Oncology (London, England)|December 18, 2025

Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trialMyung-Ju Ahn, Angelo Delmonte, Sharmistha Ghosh, et al.

Expert Review of Anticancer Therapy|December 20, 2022

Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancerJames Chih-Hsin Yang, Caicun Zhou, Pasi A Jänne, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 30, 2026

Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief ReportHidetoshi Hayashi, Byoung Chul Cho, David R Spigel, et al.

The Oncologist|May 10, 2020

Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving CrizotinibChing-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, et al.

Cancers|October 28, 2023

A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)Yvonne L E Ang, Xiaotian Zhao, Thanyanan Reungwetwattana, et al.

British Journal of Cancer|March 13, 2020

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumoursJohann de Bono, Chia-Chi Lin, Li-Tzong Chen, et al.

Pageof 33

Showing results (271-280 of 324) with videos related to

Sort By:

Pageof 33

Clinical Lung Cancer|April 15, 2018

Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 TrialsYi-Long Wu, Lecia V Sequist, Eng-Huat Tan, et al.

Proceedings of the National Academy of Sciences of the United States of America|December 21, 2007

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibJames Bean, Cameron Brennan, Jin-Yuan Shih, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2017

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension ComponentJames Chih-Hsin Yang, Myung-Ju Ahn, Dong-Wan Kim, et al.

Cancer Discovery|September 22, 2021

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung CancerPasi A Jänne, Christina Baik, Wu-Chou Su, et al.

Future Oncology (London, England)|December 18, 2025

Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trialMyung-Ju Ahn, Angelo Delmonte, Sharmistha Ghosh, et al.

Expert Review of Anticancer Therapy|December 20, 2022

Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancerJames Chih-Hsin Yang, Caicun Zhou, Pasi A Jänne, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 30, 2026

Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief ReportHidetoshi Hayashi, Byoung Chul Cho, David R Spigel, et al.

The Oncologist|May 10, 2020

Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving CrizotinibChing-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, et al.

Cancers|October 28, 2023

A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)Yvonne L E Ang, Xiaotian Zhao, Thanyanan Reungwetwattana, et al.

British Journal of Cancer|March 13, 2020

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumoursJohann de Bono, Chia-Chi Lin, Li-Tzong Chen, et al.

Pageof 33